OOIR: Observatory of International Research

Papers

(The TQCC of Veterinary and Comparative Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats	107
The development of an indirect computed tomography lymphography protocol for sentinel lymph node detection in head and neck cancer and comparison to other sentinel lymph node mapping techniques	27
Determining agreement between preoperative computed tomography lymphography and indocyanine green near infrared fluorescence intraoperative imaging for sentinel lymph node mapping in dogs with oral tu	25
Contrast‐enhanced ultrasound for sentinel lymph node mapping in the routine staging of canine mast cell tumours: A feasibility study	23
Use of indirect computed tomography lymphangiography to determine metastatic status of sentinel lymph nodes in dogs with a pre‐operative diagnosis of melanoma or mast cell tumour	23
Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs	18
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector	17
Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome	17
Peripheral blood cell ratios as prognostic factors in canine diffuse large B‐cell lymphoma treated with CHOP protocol	17
Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours	16
Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy	15
Clinicopathological characteristics and prognostic factors for canine multicentric non‐indolent T‐cell lymphoma: 107 cases	14
Cyclooxygenase‐2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas	14
Retrospective evaluation of a modified human lung cancer stage classification in dogs with surgically excised primary pulmonary carcinomas	14
To map or not to map the cN0 neck: Impact of sentinel lymph node biopsy in canine head and neck tumours	13
Outcome after surgical management of canine insulinoma in 49 cases	13
Outcome comparison between radiation therapy and surgery as primary treatment for dogs with periarticular histiocytic sarcoma: An Italian Society of Veterinary Oncology study	12
Clinical outcome in 23 dogs with exocrine pancreatic carcinoma	12
Outcome in dogs undergoing adrenalectomy for small adrenal gland tumours without vascular invasion	12
Long‐term survival of dogs with stage 4 oral malignant melanoma treated with anti‐canine PD‐1 therapeutic antibody: A follow‐up case report	12
Histologically low‐grade, yet biologically high‐grade, canine cutaneous mast cell tumours: A systematic review and meta‐analysis of individual participant data	12
Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma	12
Efficacy of frameless stereotactic radiotherapy for the treatment of presumptive canine intracranial gliomas: A retrospective analysis (2014‐2017)	11
Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4‐DNA electrovaccination: A retro	11
Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B‐cell lymphoma	11

Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate	10
Clinical presentation, treatment and outcome of canine malignant mesothelioma: A retrospective study of 34 cases	10
Neutrophil‐to‐lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas	10
Standardisation of canine meningioma grading: Inter‐observer agreement and recommendations for reproducible histopathologic criteria	10
Kynurenine 3‐monooxygenase (KMO), and signal transducer and activator of transcription 3 (STAT3) expression is involved in tumour proliferation and predicts poor survi	10
Statins downregulateYAPandTAZand exert anti‐cancer effects in canine mammary tumour cells	9
Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta‐analysis	9
Canine presumed glial brain tumours treated with radiotherapy: Is there an inferior outcome in tumours contacting the subventricular zone?	9
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials	9
Prognostic impact of clinical, haematological, and histopathological variables in 102 canine cutaneous perivascular wall tumours	9
Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog	9
A newly established canine NK‐type cell line and its cytotoxic properties	9
Adjuvant doxorubicin vs metronomic cyclophosphamide and meloxicam vs surgery alone for cats with mammary carcinomas: A retrospective study of 137 cases	9
Prospective observational study of dogs with splenic mass rupture suggests potentially lower risk of malignancy and more favourable perioperative outcomes	9
The effect of cannabidiol on canine neoplastic cell proliferation and mitogen‐activated protein kinase activation during autophagy and apoptosis	8
The oncogenic pathways of papillomaviruses	8
Evaluation of prognostic impact of pre‐treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4‐anti	8
miR‐497 induces apoptosis by the IRAK2/NF‐κB axis in the canine mammary tumour	8
Adherence to follow‐up recommendations for dogs with apocrine gland anal sac adenocarcinoma: A multicentre retrospective study	8
The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review	8
Evaluation of accuracy for ¹⁸F‐FDG positron emission tomography and computed tomography for detection of lymph node metastasis in canine oral malignant melanoma	8
Characterizing the molecular and immune landscape of canine bladder cancer	8
BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006–2019)	8
Intraoperative assessment of canine soft tissue sarcoma by deep learning enhanced optical coherence tomography	7
Fasting reduces the incidence of vincristine‐associated adverse events in dogs	7
One‐year conditional survival of dogs and cats with invasive mammary carcinomas: A concept inspired from human breast cancer	7
Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma	7
Long non‐coding RNA and transfer RNA‐derived small fragments in exosomes are potential biomarkers for canine oral melanoma	7
Unconventional diets and nutritional supplements are more common in dogs with cancer compared to healthy dogs: An online global survey of 345 dog owners	7
The feasibility and utility of optical coherence tomography directed histopathology for surgical margin assessment of canine mast cell tumours	7
Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti‐CSPG4 vaccination: A retrospective study on 68 cases (2010–2020)	7
Outcome, prognostic factors and histological characterization of canine gastrointestinal sarcomas	7
Molecular differences in mitochondrial DNA genomes of dogs with malignant mammary tumours	7
Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma	7
Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes	7
Feline and canine Merkel cell carcinoma: A case series and discussion on cellular origin	6
Shear wave elastography of lymph nodes in dogs with head and neck cancer: A pilot study	6
Extensive staging has no prognostic value in dogs with low‐risk mast cell tumours	6
Response and outcome following radiation therapy of macroscopic canine plasma cell tumours	6
Lifetime prevalence of malignant and benign tumours in companion dogs: Cross‐sectional analysis of Dog Aging Project baseline survey	6
Post‐operative complications following apocrine gland anal sac adenocarcinoma resection in dogs	6
Are B‐symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B‐cell lymphoma	6
JARID1‐targeted histone H3 demethylase inhibitors exhibit anti‐proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines	6
Carboplatin‐induced myelosuppression as related to body weight in dogs	6
Prognostic indicators for naïve canine non‐indolent T‐cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy	6
Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T‐cell lymphomas	6
Minimally invasive ethyl cellulose ethanol ablation in domesticated cats with naturally occurring head and neck cancers: Six cats	6
Canine tonsillar neoplasia and tonsillar metastasis from various primary neoplasms	6
Thymic epithelial tumours in 51 dogs: Histopathologic and clinicopathologic findings	5
Long‐term outcomes with conventional fractionated and stereotactic radiotherapy for suspected heart‐base tumours in dogs	5

Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case–control study	5
Prognostic value of pretreatment plasma D‐dimer level in dogs with intermediate to high‐grade non‐Hodgkin lymphoma	5
Treatment outcomes and target delineation utilizing CT and MRI in 13 dogs treated with a uniform stereotactic radiation therapy protocol (16 Gy single fraction) for pituitary mas	5
Risk of bladder cancer and lymphoma in dogs is associated with pollution indices by county of residence	5
A prospective, multi‐centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine na	5
Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma	5
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model	5
Evaluating optical coherence tomography for surgical margin assessment of canine mammary tumours	5
An open‐label dose escalation study evaluating tolerability and safety of a single 5‐days course of temozolomide in dogs with advanced cancer	5
Focused ultrasound tumour ablation in small animal oncology	5
Optical coherence tomography imaging of excised canine apocrine gland anal sac adenocarcinoma tumours	5
Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component	5
Ki‐67 assessment—agreeability between immunohistochemistry and flow cytometry in canine lymphoma	5
Development of synthetic microRNA‐214 showing enhanced cytotoxicity and RNase resistance for treatment of canine hemangiosarcoma	5
Outcome and postoperative complications in 73 dogs with thyroid carcinoma with gross vascular invasion managed with thyroidectomy	5
Histologic grade has a higher‐weighted value than nodal status as predictor of outcome in dogs with cutaneous mast cell tumours and overtly metastatic sentinel lymph nodes	5
Analysis of DNA methylation and TP53 mutational status for differentiating feline oral squamous cell carcinoma from non‐neoplastic mucosa: A preliminary study	5
Chemotherapy‐induced diarrhoea in dogs and its management with smectite: Results of a monocentric open‐label randomized clinical trial	5